Search research articles
Contact Us
Filters
Showing results (91-100 of 150) with videos related to
Page
of 15
Sort By:
Hepatology (Baltimore, Md.)
|
April 2, 2019
Gallbladder Dyskinesia Is Associated With an Impaired Postprandial Fibroblast Growth Factor 19 Response in Critically Ill Patients
Kiran V K Koelfat, Mark P Plummer, Frank G Schaap, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
January 23, 2010
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance
Tim C M A Schreuder, Hendrik A Marsman, Martin Lenicek, et al.
Plos One
|
April 5, 2013
Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage
Anneloes E Bohte, Laura van Dussen, Erik M Akkerman, et al.
Psychoneuroendocrinology
|
August 8, 1998
Differential effects of hydrocortisone and dexamethasone on cortisol suppression in a child psychiatric population
C C Gispen-de Wied, L M Jansen, H J Wynne, et al.
Molecular Pharmacology
|
June 20, 2003
Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions
Nita J Patel, Maciej J Zamek-Gliszczynski, Peijin Zhang, et al.
Psychoneuroendocrinology
|
September 21, 2000
Unresponsiveness to psychosocial stress in a subgroup of autistic-like children, multiple complex developmental disorder
L M Jansen, C C Gispen-de Wied, R J Van der Gaag, et al.
Scandinavian Journal of Gastroenterology
|
July 9, 2008
Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a
Huub C Gelderblom, Stefan Zeuzem, Christine J Weegink, et al.
Antiviral Therapy
|
June 27, 2007
Low-level HCV viraemia after initial response during antiviral therapy: transcription-mediated amplification predicts treatment failure
Huub C Gelderblom, Henk W Reesink, Marcel G H M Beld, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
November 23, 2007
High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection
Tim C M A Schreuder, Huub C Gelderblom, Christine J Weegink, et al.
International Journal of Obesity (2005)
|
January 24, 2014
Gallstone disease in severely obese children participating in a lifestyle intervention program: incidence and risk factors
A Heida, B G P Koot, O H vd Baan-Slootweg, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 150) with videos related to
Sort By:
Page
of 15
Hepatology (Baltimore, Md.)
|
April 2, 2019
Gallbladder Dyskinesia Is Associated With an Impaired Postprandial Fibroblast Growth Factor 19 Response in Critically Ill Patients
Kiran V K Koelfat, Mark P Plummer, Frank G Schaap, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
January 23, 2010
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance
Tim C M A Schreuder, Hendrik A Marsman, Martin Lenicek, et al.
Plos One
|
April 5, 2013
Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage
Anneloes E Bohte, Laura van Dussen, Erik M Akkerman, et al.
Psychoneuroendocrinology
|
August 8, 1998
Differential effects of hydrocortisone and dexamethasone on cortisol suppression in a child psychiatric population
C C Gispen-de Wied, L M Jansen, H J Wynne, et al.
Molecular Pharmacology
|
June 20, 2003
Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions
Nita J Patel, Maciej J Zamek-Gliszczynski, Peijin Zhang, et al.
Psychoneuroendocrinology
|
September 21, 2000
Unresponsiveness to psychosocial stress in a subgroup of autistic-like children, multiple complex developmental disorder
L M Jansen, C C Gispen-de Wied, R J Van der Gaag, et al.
Scandinavian Journal of Gastroenterology
|
July 9, 2008
Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a
Huub C Gelderblom, Stefan Zeuzem, Christine J Weegink, et al.
Antiviral Therapy
|
June 27, 2007
Low-level HCV viraemia after initial response during antiviral therapy: transcription-mediated amplification predicts treatment failure
Huub C Gelderblom, Henk W Reesink, Marcel G H M Beld, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
November 23, 2007
High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection
Tim C M A Schreuder, Huub C Gelderblom, Christine J Weegink, et al.
International Journal of Obesity (2005)
|
January 24, 2014
Gallstone disease in severely obese children participating in a lifestyle intervention program: incidence and risk factors
A Heida, B G P Koot, O H vd Baan-Slootweg, et al.
Page
of 15